# A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Source: https://onco.cc/trials/nct06754930/  
OnCo record `nct06754930` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab, SHR-8068, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC is a phase 1/2 interventional study registered as NCT06754930 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 400 participants planned, started 2025-02-18 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-1826, SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06754930
- Phase: 1/2
- Setting: A Multicenter, Open Phase IB/II Clinical Study of Safety, Tolerability, and Efficacy of SHR-1826 in Combination With Other Anti-cancer Treatment in Patients With Non-small Cell Lung Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06754930: https://clinicaltrials.gov/study/NCT06754930

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [SHR-8068](https://onco.cc/drugs/shr-8068/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06754930.json